Compare DexCom, Inc. (DXCM) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs State Street Technology Select Sector SPDR ETF — how do they compare? DexCom, Inc. trades at $84.08 (market cap $31.86B), while State Street Technology Select Sector SPDR ETF trades at $198.73 (market cap $132.55B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 4.2× DexCom, Inc.'s market cap, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| DXCM | XLK | |
|---|---|---|
Market Cap | $31.86B | $132.55B |
Volume | 3,607,070 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $92.34 | $202.00 |
52-Week Low | $54.84 | $127.49 |
Typical Hold Time | 62 Days | 50 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
XLK trades at $198.68, down 1.35% on the day, with technical indicators showing a bullish overall signal driven by strong moving average support. The ETF maintains neutral oscillators with RSI readings around 60, suggesting balanced momentum. Recent news highlights ongoing investor focus on AI sector dynamics and concentration concerns within XLK's holdings, particularly its heavy chip exposure that may limit diversification benefits despite quarterly rebalancing.
The outlook for XLK remains tied to technology sector performance and AI investment trends, with potential upside from continued enterprise software strength and semiconductor demand. Key risks include interest rate sensitivity, sector concentration, and competitive ETF alternatives offering better risk-adjusted returns. Investors should weigh XLK's cost efficiency against its mega-cap heavy structure when considering technology exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
